Dr. Judy Chou is the CEO, President and Board member of AltruBio, Inc. which is a clinical stage biotech company in San Francisco, CA.
Before taking on her current roles, she headed the global Biotech organization at Bayer Pharmaceuticals overseeing the
development, manufacturing and distribution of Bayer’s biotechnology pipeline, product portfolio & 2000+ employees. In addition,
she served as the site head for Bayer’s facility in Berkeley, CA. She is well recognized by the biomedical industry for her leadership and
has received the Most Influential Women in Business Award in 2018 by San Francisco Business Times.
Before Bayer, Dr. Chou held the role of Vice President of Pharmaceutical Operations at Pfizer, Inc./Medivation where she led the
Development and Manufacturing organizations for both biologics and small molecule products. She was also Vice President of R&D
and Manufacturing at Tanvex Biopharma and has enabled the success of the company’s IPO. Throughout Dr. Chou’s career, she has
achieved significant milestones in biologics development and multiple filings of BLAs, NDAs, and INDs of novel products and is
broadly recognized for her work at Genentech, Pfizer (Wyeth) and Abbvie (Abbott) especially in the development of breakthrough
technologies and accelerated product development.
Currently, Dr. Chou also serves as the Board of Directors of Akero Therapeutics, Inc. and California Institute of Regenerative Medicines
(CIRM); and the Advisory Board members of UC Berkeley Engineering School and Silicon Valley Women in Engineering. Before joining
the industry, Dr. Chou was a research faculty member at Harvard University Medical School. Dr. Chou obtained her Ph.D. from Yale
University and completed her post-doctoral training at Max-Planck Institute in Germany.